[{"_1":2,"_125":-5,"_126":-5},"loaderData",{"_3":4,"_9":10},"root",{"_5":6,"_7":8},"locale","id","isCms",false,"routes/tags/$slug",{"_11":12,"_13":14,"_15":16,"_112":113,"_119":115,"_123":118,"_124":-5},"slug","viral-vector","ads",[],"posts",[17],{"_6":18,"_19":20,"_11":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41,"_42":43,"_44":20,"_45":46,"_47":48,"_49":50,"_51":20,"_52":53,"_54":55,"_56":57,"_58":59,"_109":110,"_68":111},"019bb766-8fc7-7187-9ca3-07632a3d65b5","title","COVID-19 – Bio Farma targetkan penguasaan teknologi baru produksi vaksin","covid-19-bio-farma-targetkan-penguasaan-teknologi-baru-produksi-vaksin","main_id","019bb73f-28ac-70ed-836a-68ade28a117a","main_name","Nasional","main_slug","nasional","date","2021-09-23 20:12:11","author_id","019bb745-b426-73a2-9a49-5ddcb6765ea0","author_name","indowin","full_name","Indonesia Window","author_firstname","Indonesia","author_slug","indonesiawindow","content","Jakarta (Indonesia Window) - PT Bio Farma (Persero) menargetkan penguasaan dua platform teknologi baru produksi vaksin COVID-19, yakni mRNA dan viral vector sebagai strategi jangka panjang, menurut Direktur Utama Bio Farma Honesti Basyir dalam acara daring Business Performance Excellence Awards (BPEA) 2021 di Jakarta, Kamis.

Dia mengatakan, menguasai teknologi baru produksi vaksin adalah salah satu langkah untuk membangun kesiapan Indonesia dalam menghadapi kemungkinan pandemik di masa mendatang.

“Bio Farma dan semua anak perusahaannya harus mampu menguasai teknologi baru untuk menjamin resilience dari kesehatan Indonesia,\" kata Honesti, seraya menambahkan bahwa Bio Farma sebagai induk Holding BUMN farmasi menegaskan bahwa setelah mengamankan pasokan obat-obatan, langkah berikutnya dalam menangani pandemik adalah menjamin ketersediaan vaksin.

Selama pandemik COVID-19, semua negara di dunia berebut untuk mendapatkan pasokan guna menjamin program vaksinasi nasional. Indonesia yang berpenduduk 270 juta jiwa juga menghadapi masalah yang sama.

Karenanya, Bio Farma telah menetapkan strategi yang bisa menjangkau kebutuhan jangka pendek dan jangka panjang, sehingga industri vaksinasi nasional tidak bergantung pada produk-produk impor.

Honesti menjelaskan, strategi jangka pendek yang telah dilakukan oleh Bio Farma adalah membangun kerja sama dengan produsen vaksin China Sinovac dalam mengembangkan vaksin COVID-19.

Sementara untuk strategi jangka menengah, lanjut dia, Bio Farma harus bersinergi dengan beberapa kementerian dan lembaga penelitian di Indonesia guna mengembangkan vaksin produksi Indonesia.

Pengembangan vaksin produksi Indonesia yang saat ini sedang berjalan adalah vaksin Merah Putih yang bekolaborasi dengan perguruan tinggi dan Lembaga Eijkman.

Selain itu, ada vaksin BUMN yang dikembangkan bersama Baylor College of Medicine dari Amerika Serikat.

Sebelumnya, Menteri BUMN sekaligus Ketua Pelaksana Komite Penanganan COVID‑19 dan Pemulihan Ekonomi Nasional Erick Thohir berharap Indonesia bisa memproduksi vaksin sendiri melalui Program Vaksin Merah Putih atau membuka kerja sama dengan produsen vaksin lainnya.

Untuk hal tersebut, Kementerian BUMN telah bekerja sama dengan lima universitas dan dua lembaga penelitian.

Laporan: Redaksi","excerpt","Jakarta (Indonesia Window) - PT Bio Farma (Persero) menargetkan penguasaan dua platform teknologi baru produksi vaksin COVID-19, yakni mRNA dan viral vector seb...","seo_kw","seo_title","","seo_description","Bio Farma menargetkan penguasaan dua platform teknologi baru produksi vaksin COVID-19, yakni mRNA dan viral vector.","image","2021/09/spencer-davis-rxTTNlar62o-unsplash-scaled.jpg","image_alt","image_caption","Ilustrasi. (Spencer Davis on Unsplash)","image_url","https://indonesiawindow.sgp1.cdn.digitaloceanspaces.com/2021/09/spencer-davis-rxTTNlar62o-unsplash-scaled.jpg","status","publish","tags",[60,76,83,90,97,104],{"_6":61,"_62":63,"_64":65,"_11":66,"_49":-5,"_67":-5,"_68":69,"_70":69,"_71":72},"019bb744-1c2f-71ec-b547-aa3d474813de","old_id",2509,"name","vaksin Merah Putih Indonesia","vaksin-merah-putih-indonesia","description","created_at","2026-01-13T12:10:52.000000Z","updated_at","pivot",{"_73":18,"_74":61,"_68":75,"_70":75},"post_id","tag_id","2026-01-13T12:48:30.000000Z",{"_6":77,"_62":78,"_64":79,"_11":80,"_49":-5,"_67":-5,"_68":81,"_70":81,"_71":82},"019bb744-3281-70d6-9298-53840835606f",4367,"vaksin covid-19 Bio Farma","vaksin-covid-19-bio-farma","2026-01-13T12:10:58.000000Z",{"_73":18,"_74":77,"_68":75,"_70":75},{"_6":84,"_62":85,"_64":86,"_11":87,"_49":-5,"_67":-5,"_68":88,"_70":88,"_71":89},"019bb744-4ca2-72c5-a5c0-4356e1c93962",6653,"produksi vaksin covid-19 Sinovac di Bio Farma","produksi-vaksin-covid-19-sinovac-di-bio-farma","2026-01-13T12:11:05.000000Z",{"_73":18,"_74":84,"_68":75,"_70":75},{"_6":91,"_62":92,"_64":93,"_11":94,"_49":-5,"_67":-5,"_68":95,"_70":95,"_71":96},"019bb744-7067-7175-be7d-800cab114ea9",10379,"Bio Farma","bio-farma","2026-01-13T12:11:14.000000Z",{"_73":18,"_74":91,"_68":75,"_70":75},{"_6":98,"_62":99,"_64":100,"_11":101,"_49":-5,"_67":-5,"_68":102,"_70":102,"_71":103},"019bb744-7373-7108-8179-f2ed55bd8f89",10775,"teknologi mRNA","teknologi-mrna","2026-01-13T12:11:15.000000Z",{"_73":18,"_74":98,"_68":75,"_70":75},{"_6":105,"_62":106,"_64":107,"_11":12,"_49":-5,"_67":-5,"_68":102,"_70":102,"_71":108},"019bb744-7377-70b9-ae4b-609b173c821a",10777,"viral vector",{"_73":18,"_74":105,"_68":75,"_70":75},"comments",[],"2021-09-23","pagination",{"_114":115,"_116":115,"_117":118,"_119":115,"_120":115,"_121":122},"count",1,"total","perPage",12,"currentPage","totalPages","links",{},"pageSize","error","actionData","errors"]